Literature DB >> 28000524

Modulation of cancer-specific immune responses by amino acid degrading enzymes.

Elina Timosenko1, Andreas V Hadjinicolaou1, Vincenzo Cerundolo1.   

Abstract

To evade immune destruction, tumors exploit a wide range of immune escape mechanisms, including the induction of an immunosuppressive tumor microenvironment. This is mediated, in part, by amino acid degrading enzymes indoleamine 2,3-dioxygenase, tryptophan 2,3-dioxygenase, arginase 1 and arginase 2, which have emerged as key players in the regulation of tumor-induced immune tolerance. Here we describe how the expression of tryptophan- and arginine-degrading enzymes by tumor and tumor-infiltrating cells can hamper cancer-specific immune responses, and discuss how this knowledge is being exploited to develop new strategies for cancer immunotherapy.

Entities:  

Keywords:  arginase; immunosuppression; indoleamine 2,3-dioxygenase; tryptophan 2,3-dioxygenase; tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28000524     DOI: 10.2217/imt-2016-0118

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  27 in total

Review 1.  Progress on Modulating Tumor-Associated Macrophages with Biomaterials.

Authors:  Meilyn Sylvestre; Courtney A Crane; Suzie H Pun
Journal:  Adv Mater       Date:  2019-09-27       Impact factor: 30.849

2.  Membrane-Associated Proteinase 3 on Granulocytes and Acute Myeloid Leukemia Inhibits T Cell Proliferation.

Authors:  Tian-Hui Yang; Lisa S St John; Haven R Garber; Celine Kerros; Kathryn E Ruisaard; Karen Clise-Dwyer; Gheath Alatrash; Qing Ma; Jeffrey J Molldrem
Journal:  J Immunol       Date:  2018-07-18       Impact factor: 5.422

Review 3.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

Review 4.  Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes.

Authors:  William J Turbitt; Claire Buchta Rosean; K Scott Weber; Lyse A Norian
Journal:  Immunol Rev       Date:  2020-03-10       Impact factor: 12.988

5.  Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.

Authors:  Martina Mandarano; Elena Orecchini; Guido Bellezza; Jacopo Vannucci; Vienna Ludovini; Sara Baglivo; Francesca Romana Tofanetti; Rita Chiari; Elisabetta Loreti; Francesco Puma; Angelo Sidoni; Maria Laura Belladonna
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

6.  Chromatin accessibility governs the differential response of cancer and T cells to arginine starvation.

Authors:  Nicholas T Crump; Andreas V Hadjinicolaou; Meng Xia; John Walsby-Tickle; Uzi Gileadi; Ji-Li Chen; Mashiko Setshedi; Lars R Olsen; I-Jun Lau; Laura Godfrey; Lynn Quek; Zhanru Yu; Erica Ballabio; Mike B Barnkob; Giorgio Napolitani; Mariolina Salio; Hashem Koohy; Benedikt M Kessler; Stephen Taylor; Paresh Vyas; James S O McCullagh; Thomas A Milne; Vincenzo Cerundolo
Journal:  Cell Rep       Date:  2021-05-11       Impact factor: 9.423

Review 7.  Notch Signaling in Macrophages in the Context of Cancer Immunity.

Authors:  Tanapat Palaga; Wipawee Wongchana; Patipark Kueanjinda
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

8.  β-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas.

Authors:  Jérémie Nsengimana; Jon Laye; Anastasia Filia; Sally O'Shea; Sathya Muralidhar; Joanna Poźniak; Alastair Droop; May Chan; Christy Walker; Louise Parkinson; Joanne Gascoyne; Tracey Mell; Minttu Polso; Rosalyn Jewell; Juliette Randerson-Moor; Graham P Cook; D Timothy Bishop; Julia Newton-Bishop
Journal:  J Clin Invest       Date:  2018-04-16       Impact factor: 14.808

Review 9.  Next generation of immune checkpoint therapy in cancer: new developments and challenges.

Authors:  Julian A Marin-Acevedo; Bhagirathbhai Dholaria; Aixa E Soyano; Keith L Knutson; Saranya Chumsri; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388

Review 10.  Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts.

Authors:  Linda Ziani; Salem Chouaib; Jerome Thiery
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.